Risk stratification after radical prostatectomy in men with pathologically organ-confined prostate cancer using volume-weighted mean nuclear volume

Prostate

Volumn 64, Issue 3, 2005, Pages 217-223

  Matsui, Yoshiyuki ^a,c   Utsunomiya, Noriaki ^a   Ichioka, Kentaro ^a   Ueda, Norihumi ^a   Yoshimura, Koji ^a   Terai, Akito ^a   Arai, Yoichi ^b  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Cancer volume; Mean nuclear volume; Prognosis; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CHEMICAL ANALYSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEAN NUCLEAR VOLUME; MEASUREMENT; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL SIGNIFICANCE; STEREOMETRY; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 22144474420     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20222     Document Type: Article

References (31)

1. D'Amico AV, Whittington R, Malkowicz SB, Fondurulla J, Chen MH, Tomaszewski JE, Wein A. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized disease. J Urol 1998;160:2098-2101.
2. Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997;50:93-99.
3. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prosta-tectomy: A study of 196 cases with long-term follow-up. J Urol 1993;150:135-141.
4. Kausik SJ, Blute ML, Sebo TJ, Leibovich BC, Bergstralh EJ, Slezak J, Zincke H. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer 2002;95:1215-1219.
5. Debras B, Guillonneau B, Bougaran J, Chambon E, Vallancien G. Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen. Rationale for seminal vesicle biopsies. Eur Urol 1998;33:271-277.
6. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20(4):713-725.
7. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5 Pt 2):1850-1857.
8. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, Epstein JI. Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992;70:161-168.
9. Veltri RW, Partin AW, Miller MC. Quantitative nuclear grade (QNG): A new image analysis-based biomarker of clinically relevant nuclear structure alterations. J Cellular Biochemistry 2000;35:151-157.
10. Gunderson HJG, Jensen EB. Particle sizes and their distributions estimated from line- and point-sampled intercepts. Including graphical unfolding. J Microsc 1983;131:291-310.
11. Nielsen K, Berlid GH, Bruun E, Jorgensen PE, Weis N. Stereological estimation of mean nuclear volume in prostatic cancer, the reproducibility and the possible value of estimation on repeated biopsies in the course of disease. J Microsc 1989; 154:63-69.
12. Arai Y, Okubo K, Terada N, Matsuta Y, Egawa S, Kuwao S, Ogura K. Volume-weighted mean nuclear volume predicts tumor biology of clinically organ-confined prostate cancer. Prostate 2001;46:134-141.
13. Fujikawa K, Matsui Y, Kobayashi T, Miura K, Oka H, Fukuzawa S, Takeuchi H. Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume. J Urol 2000;164:1587-1590.
14. Sobin LH, Wittekind Ch, editors. International Union Against Cancer (UICC). TNM classification of malignant tumors (5th edition) New York: Wiley-Liss & sons Inc; 1997.
15. Jensen EB, Gunderson HJG. Fundamental Stereological formulae based on isotropically oriented probes through fixed points with applications to particle analysis. J Microsc 1989;153:249.
16. Freedl SJ, Partin AW, Epstein JI, Walsh PC. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer 2004;100: 1646-1649.
17. Bianco FJ Jr., Wood DP Jr., Cher ML, Powell IJ, Souza JW, Pontes JE. Ten-year survival after radical prostatectomy: Specimen Gleason score is predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003;1:242-247.
18. Ramos CG, Roehl KA, Antenor JA, Humphrey PA, Catalona WJ. Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer. J Urol 2004;172: 137-140.
19. Veltri RW, Miller MC, Mangold LA, O'Dowd GJ, Epstein JI, Partin AW. Prediction of pathological stage in patients with clinical stage Tie prostate cancer: The new challenge. J Urol 2002;168:100-104.
20. Boone CW, Lieberman R, Mairinger T, Palcic B, Bacus J, Bartels P. Computer-assisted image analysis-derived intermediate end-points. Urology 2001;57(Suppl):129-131.
21. Bartels PH, Montironi R, Duval da Silva V, Hamilton PW, Thompson D, Vaught L, Barteis HG. Tissue architecture analysis in prostate cancer and its precursors: An innovative approach to computerized histometry. Eur Urol 1999;35:484-491.
22. Baluska F, Barlow PW. The role of the microtubular cytoskeleton in determining nuclear chromatin structure and passage of maize root cells through the cell cycle. Eur J Cell Biol 1993;61: 160-167.
23. Ogura K, Fukuzawa S, Habuchi T, Ogawa O, Yoshida O. Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder. Int J Urol 1997;4:561-566.
24. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: Relationship to local and distant spread. Hum Pathol 1992;23:258-266.
25. Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H. Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol 2002;41:155-161.
26. Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP, Bostwick DG. Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer 1999;86:1775-1782.
27. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-1824.
28. Allsbrook WC Jr., Mangold KA, Yang X, Epstein JI. The Gleason grading system. J Urol Pathol 1999;10:141-157.
29. Fujikawa K, Aoyama T, Itoh T, Nishio Y, Miyakawa M, Sasaki M. Volume-weighted mean nuclear volume. Is this new prognosticator comparable in different institutions? Anal Quant Cytol Histol 2000;22:55-62.
30. Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999;161:1238-1243.
31. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: Correlation with patient survival. Cancer Res 1997;57:3189-3193.